Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
- Category: Proteins and Peptides
- Published on Friday, 22 December 2017 11:02
- Hits: 898
Topline Data from Second Clinical Indication Expected First Half of 2019
CAMBRIDGE, MA, USA I December 21, 2017 I Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has initiated dosing in the Company’s Phase 2 clinical trial evaluating RA101495 SC for the treatment of generalized myasthenia gravis (gMG). gMG is a rare, complement-mediated, autoimmune disease that causes weakness in skeletal muscles. Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as a novel, subcutaneously-administered (SC) inhibitor of complement component 5 (C5). RA101495 SC is currently in clinical development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
“Following promising Phase 1 data demonstrating a favorable pharmacokinetic and pharmacodynamic profile for RA101495, this Phase 2 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of RA101495 in gMG,” said James F. Howard, MD, University of North Carolina School of Medicine. “RA101495 potently inhibits C5, a validated therapeutic target in myasthenia. The convenient, once-daily, SC, self-administration schedule of RA101495 may enable treatment of a broad population of gMG patients.”
The Phase 2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, and preliminary efficacy of RA101495 SC in patients with gMG. The trial will enroll approximately 36 patients. At the outset of the 12-week treatment period, patients will be randomized in a 1:1:1 ratio and will receive daily, SC doses of 0.1 mg/kg of RA101495, 0.3 mg/kg of RA101495, or matching placebo. The primary efficacy endpoint is change in Quantitative Myasthenia Gravis (QMG) score from baseline to week 12. All patients will have the opportunity to receive RA101495 SC in a long-term extension study.
“gMG is a rare, autoimmune disease characterized by autoantibodies targeting proteins critical for the normal transmission of electrical signals from nerves to muscles,” said Nancy Law, CEO of the Myasthenia Gravis Foundation of America. “Patients with gMG have limited treatment options. Given the significant unmet need in this patient population, we are encouraged by the initiation of this Phase 2 trial, and we look forward to determining the potential clinical benefit of this novel, once-daily, subcutaneously-administered C5 inhibitor.”
Myasthenia gravis (MG) is a chronic, autoimmune, neuromuscular disease characterized by weakness and fatigue of voluntary muscles. Patients with MG present with muscle weakness that becomes increasingly severe with repeated use and recovers with rest. Weakness can be localized to specific muscles, such as those responsible for eye movements, but often progresses to affect a broader range, including head, limb, and respiratory muscles. This progression is often described as the generalized, or severe, form of the disease. gMG is estimated to affect over 80,000 individuals worldwide.
“Initiation of dosing in our Phase 2 trial evaluating RA101495 in gMG is a critical step in the advancement of a potential novel therapy for patients with this disabling autoimmune disorder, and we expect topline data from this trial in the first half of 2019,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “We continue to be encouraged by the positive interim data from our ongoing Phase 2 program evaluating RA101495 in patients with PNH, and we remain focused on fully maximizing the potential of RA101495’s safety, efficacy, and ease of administration to expand patient access across a range of C5-mediated disorders.”
About RA101495 SC
Ra Pharma is developing RA101495 SC for paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), and lupus nephritis (LN). The product is designed for convenient, once-daily, subcutaneous (SC) self-administration. RA101495 SC is a synthetic, macrocyclic peptide discovered using Ra Pharma’s powerful proprietary drug discovery technology. The peptide binds complement component 5 (C5) with sub-nanomolar affinity and allosterically inhibits its cleavage into C5a and C5b upon activation of the classical, alternative, or lectin pathways. By binding to a region of C5 corresponding to C5b, RA101495 SC also disrupts the interaction between C5b and C6 and prevents assembly of the membrane attack complex (MAC). This activity defines an additional, novel mechanism for the inhibition of C5 function. To learn more about RA101495 SC, please visit: http://rapharma.com/pipeline/ra101495/.
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.
SOURCE: Ra Pharmaceuticals